Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Blagden

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 14, 2025
Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical TrialsJia Liu, Max Farrow, Lesley Seymour, et al.
Lancet (London, England)|December 4, 2019
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trialAndrew R Clamp, Elizabeth C James, Iain A McNeish, et al.
The Lancet. Oncology|June 11, 2022
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trialAndrew R Clamp, Elizabeth C James, Iain A McNeish, et al.
Cell Reports. Medicine|April 1, 2025
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumorsRuth Plummer, Mikael H Sodergren, Rose Hodgson, et al.
Nature Reviews. Cancer|October 24, 2015
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancerDavid D Bowtell, Steffen Böhm, Ahmed A Ahmed, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 14, 2025
Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical TrialsJia Liu, Max Farrow, Lesley Seymour, et al.
Lancet (London, England)|December 4, 2019
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trialAndrew R Clamp, Elizabeth C James, Iain A McNeish, et al.
The Lancet. Oncology|June 11, 2022
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trialAndrew R Clamp, Elizabeth C James, Iain A McNeish, et al.
Cell Reports. Medicine|April 1, 2025
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumorsRuth Plummer, Mikael H Sodergren, Rose Hodgson, et al.
Nature Reviews. Cancer|October 24, 2015
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancerDavid D Bowtell, Steffen Böhm, Ahmed A Ahmed, et al.
Pageof 4